{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:19:04Z","timestamp":1791256744146,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":1254,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Nelia et Amadeo Barletta Foundation"},{"name":"Gelu Foundation"},{"name":"Lugano Anglican Church of St. Edward the Confessor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1093\/annonc\/mdw131","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T02:13:49Z","timestamp":1457576029000},"page":"1123-1128","source":"Crossref","is-referenced-by-count":31,"title":["Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas"],"prefix":"10.1016","volume":"27","author":[{"given":"E.","family":"Gaudio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tarantelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Kwee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Barassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ponzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Cascione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Targa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Stathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Goodstal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Zucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bertoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw131_bb0010","series-title":"WHO Classification of tumours of haematopoietic and lymphoid tissues","first-page":"439","author":"Swerdlow","year":"2008"},{"key":"10.1093\/annonc\/mdw131_bb0015","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nri3487","article-title":"New insights into pre-BCR and BCR signalling with relevance to B cell malignancies","volume":"13","author":"Rickert","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1093\/annonc\/mdw131_bb0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","article-title":"Targeting pathological B cell receptor signalling in lymphoid malignancies","volume":"12","author":"Young","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1093\/annonc\/mdw131_bb0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/bjh.13065","article-title":"Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma","volume":"167","author":"Blachly","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdw131_bb0030","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/annonc\/mdv019","article-title":"Genetic lesions in diffuse large B-cell lymphoma","volume":"26","author":"Testoni","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw131_bb0035","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1158\/1078-0432.CCR-14-0010","article-title":"Ibrutinib for the treatment of mantle cell lymphoma","volume":"20","author":"Herrera","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw131_bb0040","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1078-0432.CCR-14-2034","article-title":"Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma","volume":"21","author":"Yang","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw131_bb0045","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1182\/blood-2002-12-3647","article-title":"Map kinase signaling pathways and hematologic malignancies","volume":"101","author":"Platanias","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw131_bb0050","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1182\/blood-2004-07-2669","article-title":"Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells","volume":"105","author":"Petlickovski","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw131_bb0055","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2011-07-370403","article-title":"Surface IgM stimulation induces MEK1\/2-dependent MYC expression in chronic lymphocytic leukemia cells","volume":"119","author":"Krysov","year":"2012","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw131_bb0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1478-811X-10-43","article-title":"Global gene expression changes of in vitro stimulated human transformed germinal centre B cells as surrogate for oncogenic pathway activation in individual aggressive B cell lymphomas","volume":"10","author":"Schrader","year":"2012","journal-title":"Cell Commun Signal"},{"key":"10.1093\/annonc\/mdw131_bb0065","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw131_bb0070","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/bjh.12974","article-title":"Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells","volume":"166","author":"Ma","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdw131_bb0075","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/leu.2014.263","article-title":"Functional characterization of BTKC481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors","volume":"29","author":"Cheng","year":"2014","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdw131_bb0080","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/leu.2014.187","article-title":"The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's macroglobulinemia","volume":"29","author":"Cao","year":"2015","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdw131_bb0085","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00280-013-2121-1","article-title":"PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types","volume":"71","author":"Britten","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdw131_bb0090","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","article-title":"The clinical development of MEK inhibitors","volume":"11","author":"Zhao","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1093\/annonc\/mdw131_bb0095","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS-ERK signalling in cancer: promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1093\/annonc\/mdw131_bb0100","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1080\/1042819022386815","article-title":"Inhibition of MEK induces fas expression and apoptosis in lymphomas overexpressing Ras","volume":"43","author":"Kalas","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdw131_bb0105","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood-2011-03-340109","article-title":"The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma","volume":"118","author":"Bhalla","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw131_bb0110","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1158\/1535-7163.MCT-11-0505","article-title":"Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212","volume":"11","author":"Jing","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdw131_bb0115","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdw131_bb0120","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdw131_bb0125","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2141.2010.08127.x","article-title":"Blockade of the MEK\/ERK signalling cascade by AS703026, a novel selective MEK1\/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo","volume":"149","author":"Kim","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdw131_bb0130","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-14-1561","article-title":"The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs","volume":"21","author":"Boi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdw131_bb0135","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.18632\/oncotarget.3239","article-title":"Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response","volume":"6","author":"Mensah","year":"2015","journal-title":"Oncotarget"},{"key":"10.1093\/annonc\/mdw131_bb0140","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdw131_bb0145","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1080\/10428190802353591","article-title":"Preclinical versus clinical drug combination studies","volume":"49","author":"Chou","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdw131_bb0150","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.molcel.2014.12.030","article-title":"Interferon alpha\/beta enhances the cytotoxic response of MEK inhibition in melanoma","volume":"57","author":"Litvin","year":"2015","journal-title":"Mol Cell"},{"key":"10.1093\/annonc\/mdw131_bb0155","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1054\/bjoc.2000.1263","article-title":"Interferon-alpha2b reduces phosphorylation and activity of MEK and ERK through a Ras\/Raf-independent mechanism","volume":"83","author":"Romerio","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdw131_bb0160","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bbamcr.2005.06.003","article-title":"Rapid inhibition of MAPK signaling and anti-proliferation effect via JAK\/STAT signaling by interferon-alpha in hepatocellular carcinoma cell lines","volume":"1745","author":"Inamura","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1093\/annonc\/mdw131_bb0165","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1002\/ijc.28236","article-title":"Antitumor activity of pimasertib, a selective MEK 1\/2 inhibitor, in combination with PI3K\/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells","volume":"133","author":"Martinelli","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdw131_bb0170","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw131_bb0175","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1073\/pnas.1311846111","article-title":"High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells","volume":"111","author":"Mathews Griner","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdw131_bb0180","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/leu.2013.249","article-title":"Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma","volume":"28","author":"Axelrod","year":"2014","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdw131_bb0185","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3324\/haematol.2012.068510","article-title":"Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas","volume":"98","author":"Martin-Sanchez","year":"2013","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdw131_bb0190","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/10428194.2014.917639","article-title":"Dual inhibition of phosphatidylinositol 3-kinase\/mammalian target of rapamycin and mitogen activated protein kinase pathways in non-Hodgkin lymphoma","volume":"56","author":"Anders","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdw131_bb0195","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/bjc.2012.70","article-title":"The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition","volume":"106","author":"Haagensen","year":"2012","journal-title":"Br J Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419356480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419356480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/6\/1123\/19446589\/mdw131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:58:34Z","timestamp":1624694314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419356480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0923753419356480"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw131","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}